about
Apoptosis induced by knockdown of uPAR and MMP-9 is mediated by inactivation of EGFR/STAT3 signaling in medulloblastomaRNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivoRestoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosisMMP-9, uPAR and cathepsin B silencing downregulate integrins in human glioma xenograft cells in vitro and in vivo in nude mice.Co-depletion of cathepsin B and uPAR induces G0/G1 arrest in glioma via FOXO3a mediated p27 upregulation.Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell linesRegulation of glioblastoma progression by cord blood stem cells is mediated by downregulation of cyclin D1.SPARC overexpression inhibits cell proliferation in neuroblastoma and is partly mediated by tumor suppressor protein PTEN and AKT.Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells.Down-regulation of uPAR and cathepsin B retards cofilin dephosphorylation.Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas.SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA.Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptorRNA interference-mediated simultaneous down-regulation of urokinase-type plasminogen activator receptor and cathepsin B induces caspase-8-mediated apoptosis in SNB19 human glioma cellsuPA and uPAR shRNA inhibit angiogenesis via enhanced secretion of SVEGFR1 independent of GM-CSF but dependent on TIMP-1 in endothelial and glioblastoma cells.Transfection with anti-p65 intrabody suppresses invasion and angiogenesis in glioma cells by blocking nuclear factor-kappaB transcriptional activity.Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway.RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis.RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis.Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice.Proteases and glioma angiogenesis.RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth.Simultaneous downregulation of uPAR and MMP-9 induces overexpression of the FADD-associated protein RIP and activates caspase 9-mediated apoptosis in gliomas.Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma.Concepts in in vivo siRNA delivery for cancer therapy.Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases.Drugs in preclinical and early-stage clinical development for pancreatic cancer.Brief overview of selected approaches in targeting pancreatic adenocarcinoma.Down-regulation of integrin alpha(v)beta(3) expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes.Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis.Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis.Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion.Chronic radiation exposure of neuroblastoma cells reduces nMYC copy numberRNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas.Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth.Targeting the Expression of Cathepsin B Using CRISPR/Cas9 System in Mammalian Cancer Cells.
P50
Q24298860-B372B6C5-F108-4F73-A001-81CF67B059A7Q24539093-56A2ED4C-709A-4396-99B7-0CC094E44FBEQ24681706-C87F7280-698C-4413-89AE-062E02110D21Q33640030-74248ACF-E301-4FDC-86C2-379E0E12D2A4Q33640030-940F03DD-7381-4F60-AF77-9570D877E5D2Q33641523-EE8C69F6-8DB5-4FCE-9CD3-7FA7808D0CD5Q33678848-E9C27832-4198-475D-BA99-AB0E3F89655AQ33859439-D0079C89-9C35-42A9-B7E4-1CEA45FADE68Q34261684-53050733-D3D8-4C9E-A493-D3ABB4729BACQ34293732-C38123EB-B7E3-4D98-899E-10B20D1E0F91Q34343134-CEF8326F-8A05-4D7F-AC4D-B6E4C2C7C05DQ34410643-9426D8B1-F53B-4DE9-9342-E76942312115Q35167158-2AF7CDAF-C127-4549-84AF-8951A91949D8Q35533533-F6CBF1F3-F938-4804-8665-679EA34771C1Q35630444-2D2E5958-3F46-49C1-A09F-B413954F869AQ35713784-07DB4257-597E-40FD-AA95-C9CB0CDCF981Q35781926-FF84326A-7716-425B-8220-ADD3DD7F13BAQ35867494-2FFFFF86-5A8B-4FFC-9DAC-5087D52B54B2Q35920401-53E1481E-14A4-43EB-9795-9DE1EF101C44Q36074431-7094714C-0862-4FB1-BAF2-765059B1F42AQ36274412-1D90D377-B853-429E-A7EF-4D8D7BA6BCD6Q36359237-D41FAD4A-8A02-41FA-BAE0-CF4D1B746F88Q36676608-295F2785-A9C8-4471-A567-FB6E0D6FBF6EQ36925536-9AE7762D-AE88-46E6-B9AB-9DA34E8587BEQ36952294-7ABCF3E6-E530-4B34-A6ED-76BF6085AA4BQ37217876-00D34C84-3D9B-40FE-9577-8A7D7E32C7DAQ37419308-40120E2A-D1B7-4429-965E-EAF64E1D2871Q37973133-15F44980-85E5-4F4D-B0AF-135639F2EE2CQ38199723-B3E0D91A-6312-4094-90C6-D1EBF7001A9EQ38296528-8FB14551-A66C-4EF2-88E8-07DC4DB7EFE8Q40560262-6EBE300A-1C77-4A54-94CA-E60B4359A391Q40637766-8CB819A8-0516-4B3F-A76B-054BCB3C687FQ40688961-92F601B4-94CF-4E0C-BBE5-C83B5F3550E5Q41620256-5A2F9A0B-B948-42BE-9A95-56DEC196B3A4Q45878050-BD462DA5-F1E5-40F6-B76B-0C4E05539DA7Q48308618-59C720A2-DFE8-425F-8675-8A9FFB5EFCAEQ50109706-AF2F7B5D-A0AA-40EF-98F1-8CCA29F4A4C1
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Christopher S Gondi
@ast
Christopher S Gondi
@en
Christopher S Gondi
@es
Christopher S Gondi
@nl
type
label
Christopher S Gondi
@ast
Christopher S Gondi
@en
Christopher S Gondi
@es
Christopher S Gondi
@nl
prefLabel
Christopher S Gondi
@ast
Christopher S Gondi
@en
Christopher S Gondi
@es
Christopher S Gondi
@nl
P106
P21
P31
P496
0000-0002-3036-9920